{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"58357a1d9bf15d760ff96b752ebe37233ffda878b065c1f9f1e07719a779e1db","attributes":{"feedName":"fda","feedSource":"fda","title":"Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling","description":"Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it’s wholly owned subsidiary, Dr Reddy’s Laboratories, Inc is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetram in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags to the hospital level in U.S.A.","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-laboratories-continues-its-voluntary-nationwide-recall-levetiracetam-054-sodium-chloride","publicationDate":"2019-02-04T15:21:00.000Z","state":"sent","affected":[],"allergens":[],"audience":["consumers","professionals"],"categories":["drugs"],"contaminants":[],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5d9e68ae8b079e002a251488"}}}